Journal
JOURNAL OF MEDICINAL CHEMISTRY
Volume 57, Issue 16, Pages 7031-7041Publisher
AMER CHEMICAL SOC
DOI: 10.1021/jm500749d
Keywords
-
Categories
Funding
- University Cancer Research Fund
- Federal Funds from the National Cancer Institute, National Institute of Health [HHSN261200800001E]
- NIH [1R01CA137078]
- BCRF
Ask authors/readers for more resources
We previously reported a potent small molecule Mer tyrosine kinase inhibitor UNC1062. However, its poor PK properties prevented further assessment in vivo. We report here the sequential modification of UNC1062 to address DMPK properties and yield a new potent and highly orally bioavailable Mer inhibitor, 11, capable of inhibiting Mer phosphorylation in vivo, following oral dosing as demonstrated by pharmaco-dynamic (PD) studies examining phospho-Mer in leukemic blasts from mouse bone marrow. Kinome profiling versus more than 300 kinases in vitro and cellular selectivity assessments demonstrate that 11 has similar subnanomolar activity against Flt3, an additional important target in acute myelogenous leukemia (AML), with pharmacologically useful selectivity versus other kinases examined.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available